-
Company Insights
Innovation and Patenting activity of AVROBIO Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of AVROBIO Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JMKX-000623 in Neuropathic Pain (Neuralgia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JMKX-000623 in Neuropathic Pain (Neuralgia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. JMKX-000623 in Neuropathic Pain (Neuralgia) Drug Details: JMKX-000623 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GLR-2007 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GLR-2007 in Solid Tumor Drug Details: GLR-2007 is under development for the treatment of advanced...
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s Zilovertamab vedotin
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AVRRD-04 in Cystinosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AVRRD-04 in Cystinosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.AVRRD-04 in CystinosisDrug Details:AVRRD-04 is under development for the treatment of cystinosis. It is...
-
Company Profile
NewAVROBIO Inc – Company Profile
AVROBIO Inc (AVROBIO) is a biopharmaceutical company. It strives to develop potentially curative ex vivo lentiviral-based gene therapies for rare diseases. The company’s products comprise AVR-RD-02 for Gaucher disease, AVR-RD-05 for Hunter syndrome, AVR-RD-03 for Pompe disease and AVR-RD-04 for cystinosis among others. AVROBIO’s lentiviral-based gene therapies utilize hematopoietic stem cells that are collected from the patient and then developed with a lentiviral vector to include a functional copy of the gene that is defective in the target disease. The...
Add to Basket -
Product Insights
Acute Myelocytic Leukemia (AML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
AML Pipeline Products Market Report Overview Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the bloodstream and spread to the other parts of the body. Symptoms of AML include fatigue, fever, bleeding, breathing problems, and weight loss. The predisposing factors involved are exposed to...
-
Product Insights
Gaucher Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Gaucher disease is a rare genetic disorder occurs due to lacks an enzyme called glucocerebrosidase. Symptoms include cognitive impairment, enlarged spleen, severe swelling, lung disease, fatigue, and seizures. Treatment includes enzyme replacement therapy. The Gaucher Disease pipeline market research report provides comprehensive information on the therapeutics under development for Gaucher Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological...